Portal de Periódicos da CAPES

Revisão Acesso aberto Produção Nacional Revisado por pares

BIBTEX RIS

Mesenchymal Stem Cell Therapy in Diabetic Cardiomyopathy

2022; Multidisciplinary Digital Publishing Institute; Volume: 11; Issue: 2 Linguagem: Inglês

10.3390/cells11020240

2073-4409

Jaqueline da Silva, Renata Guedes de Jesus Gonçalves, Juliana Ferreira Vasques, Bruna Rocha, Bianca Nascimento-Carlos, Tadeu L. Montagnoli, Rosalia Méndez‐Otero, Mauro Paes Leme de Sá, Gisele Zapata‐Sudo,

Electrospun Nanofibers in Biomedical Applications

The incidence and prevalence of diabetes mellitus (DM) are increasing worldwide, and the resulting cardiac complications are the leading cause of death. Among these complications is diabetes-induced cardiomyopathy (DCM), which is the consequence of a pro-inflammatory condition, oxidative stress and fibrosis caused by hyperglycemia. Cardiac remodeling will lead to an imbalance in cell survival and death, which can promote cardiac dysfunction. Since the conventional treatment of DM generally does not address the prevention of cardiac remodeling, it is important to develop new alternatives for the treatment of cardiovascular complications induced by DM. Thus, therapy with mesenchymal stem cells has been shown to be a promising approach for the prevention of DCM because of their anti-apoptotic, anti-fibrotic and anti-inflammatory effects, which could improve cardiac function in patients with DM.